Drug intelligence / Profile preview

ginseng secondary glycosides H

Development stage
Unknown
Lead developer
West China Hospital of Sichuan University
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Ginseng secondary glycosides H is a botanical drug candidate composed of rare ginsenosides derived from the transformation or hydrolysis of primary ginseng saponins. Developed by the West China Hospital of Sichuan University, it is formulated as dripping pills for oral administration. The drug is primarily investigated for the treatment of advanced non-small cell lung cancer (NSCLC) in patients exhibiting Qi deficiency syndrome, a classification in Traditional Chinese Medicine (TCM). Secondary ginsenosides, such as Rg3 and Rh2, are known to exhibit anti-tumor activities, including the inhibition of cell proliferation, induction of apoptosis, and anti-angiogenic effects. This specific preparation is being evaluated in clinical trials for patients who are not candidates for or decline standard anticancer therapies.

Other names
Ginseng secondary glycoside H人参次生苷H
02

Targets

NF-κBVEGFA (Vascular endothelial growth factor A)CASP9 (Caspase-9)CASP3 (Caspase-3)

Beyond the preview

Go deeper on ginseng secondary glycosides H.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ginseng secondary glycosides H.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call